Introduction
Graves' orbitopathy (GO) constitutes a major clinical and therapeutic challenge (1, 2) . GO is an autoimmune disorder representing the commonest and most important extrathyroidal manifestation of Graves' disease, but it may occur in patients without current or prior hyperthyroidism (euthyroid or ophthalmic Graves' disease) or in patients who are hypothyroid due to chronic autoimmune (Hashimoto's) thyroiditis (3, 4) . Although the pathogenesis of GO (5) (6) (7) (8) (9) is beyond the scope of this document, attention is drawn to the link between the orbit and thyroid, which has important clinical and therapeutic implications. Optimal management of GO requires a coordinated approach addressing the thyroid dysfunction and the orbitopathy (10, 11) .
GO is often mild and self-limiting, and probably declining in frequency, with only 3-5% of cases posing a threat to eyesight (3, 4) . The onset and progression of GO are influenced by factors that are potentially controllable such as cigarette smoking, thyroid dysfunction, and choice of treatment modalities for hyperthyroidism (12, 13) .
Suboptimal management of patients with GO appears to be widespread (2) . The objective of this document is to provide practical information for managing patients with GO, for both non-specialists and those with special interest and expertise in this condition, and thus improve the outcomes of patients with GO. It is hoped that the document will also be useful to specialist nurses, orthoptists, and those involved in managerial roles, and that it will provide a focus for audit and research. Randomized clinical trials (RCTs) are infrequent in this field. The document should therefore be considered as a consensus statement rather than a guideline.
Recommendations
Referral to combined thyroid eye clinics and initial assessment a. Should all patients with GO be referred to combined thyroid eye clinics (10)? (Box 1) † All patients with GO, except for the mildest cases, should either be managed by a physician with particular expertise in managing GO or better be referred to a combined thyroid eye clinics for further assessment and management. † Many patients with GO never reach combined thyroid eye clinics or are referred too late to benefit from treatments (2) . This practice is undesirable and may result in a suboptimal outcome and sometimes loss of vision. † A simple tool for assessing patients by generalist is recommended (1) and is summarized in Box 1.
Management issues of GO that should be addressed by both non-specialists and specialists
Smoking and GO a. Is smoking related to the occurrence, severity, and progression of GO? (Box 2) † There is a strong and consistent association between smoking and GO (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . † Smokers suffer more severe GO (14, 15, 17) than non-smokers. † A dose-response relationship between the numbers of cigarettes smoked per day and the probability of developing GO has been demonstrated (21) . † Smoking increases the likelihood of progression of GO after radioiodine therapy for hyperthyroidism (25) (26) (27) . † Some evidence suggests that smoking either delays or worsens the outcomes of treatments for GO (28, 29) . † There is some retrospective evidence that quitting smoking is associated with a better outcome of GO (19, 21) .
Management of hyperthyroidism in patients with GO
a. Is correction of thyroid dysfunction important for GO? (Box 3) † Patients with uncontrolled thyroid function (both hyper-and hypothyroidism) are more likely to have severe GO than patients with euthyroidism (30-32). b. Is there a relationship between the modality of treatment for hyperthyroidism and the course of GO? † Antithyroid drug (ATD) therapy (27, 30, 33) and thyroidectomy do not affect the course of GO (26, (34) (35) (36) , although the role of the latter requires further investigation. † No particular ATD or regimen, nor any type of thyroidectomy (subtotal or total) has been demonstrated to have any advantages in terms of outcome of GO. † The few available RCTs on the effects of radioiodine therapy on GO show that a definite proportion of patients (w15%) develop new eye disease or experience the progression of pre-existing GO within 6 months after radioiodine therapy (25) (26) (27) . In w5% of patients, worsening persisted at 1 year and required additional treatment (25) . This risk is almost eliminated by giving a short course (w3 months) of oral glucocorticoids (GCs) after radioiodine therapy (25, 27) , and avoiding post-treatment hypothyroidism (32) . Shorter administration of oral GCs (1-2 months) may be equally protective. Indicates the absence of directly applicable studies of good quality † The risk of exacerbation of pre-existing GO following radioiodine therapy is negligible and steroid cover can be avoided in patients with inactive eye disease, as long as post-radioiodine hypothyroidism is avoided (37, 38) , and other risk factors for GO progression, including smoking (28) and high thyrotrophin receptor antibody levels (O7.5 IU/l) (39) , are absent (40) .
Other simple measures that may alleviate symptoms a. Are there worthwhile simple measures that can relieve some of the symptoms of GO? (Box 4) † The symptoms of corneal exposure (grittiness, watering, and photophobia) often accompany active GO, and may persist if lid retraction is severe. Such patients benefit from lubricants (3, 4) . † Nocturnal ointment is of great benefit for incomplete eyelid closure provided the cornea is protected (3, 4) . Otherwise, urgent intervention will be required. † Prisms may control intermittent or constant diplopia, and sleeping with head up may reduce morning eyelid swelling. Diuretics are rarely useful. † Botulinum toxin injection can reduce upper lid retraction (41) , but this procedure should be carried out in specialist centers.
Management issues of GO, which should be addressed in specialist centers
Grading severity and activity of GO a. What protocol should be followed for detailed assessment of patients with GO in specialist centers? (Boxes 5 and 6) † Making treatment decisions for patients with GO requires detailed assessment of the eyes, understanding of the natural history of the disease, insight into the impact of GO on the individual patient (42) , and appreciation of the efficacy and side effects of therapies.
Box 1 Tools for referral of patients with GO to combined thyroid eye clinics
Primary-care physicians, general practitioners, general internists, and specialists, who have no particular expertise in managing GO, should refer patients with GO, except for the mildest cases, to combined thyroid eye clinics for further assessment and management (IV, C).
Assessments and criteria for referral recommended by EUGOGO (IV, C).
-Patients with a history of Graves' disease, who have neither symptoms nor signs of GO, require no further ophthalmological assessments and need not be referred to a combined thyroid eye clinic.
-Patients with unusual presentations (unilateral GO or euthyroid GO) should be referred, however mild their symptoms or signs, in order to make an accurate diagnosis.
-All other cases should be screened according to the protocol below (IV, C), as recommended previously by Wiersinga et al. (1) Refer urgently if any of the following are present: Symptoms Unexplained deterioration in vision Awareness of change in intensity or quality of color vision in one or both eyes History of eye(s) suddenly 'popping out' (globe subluxation)
Signs
Obvious corneal opacity Cornea still visible when the eyelids are closed Disk swelling
Refer non-urgently if any of the following are present: Symptoms Eyes abnormally sensitive to light: troublesome or deteriorating over the past 1-2 months Eyes excessively gritty and not improving after 1 week of topical lubricants Pain in or behind the eyes: troublesome or deteriorating over the past 1-2 months Progressive change in appearance of the eyes and/or eyelids over the past 1-2 months Appearance of the eyes has changed causing concern to the patient Seeing two separate images when there should only be one
Troublesome eyelid retraction Abnormal swelling or redness of eyelid(s) or conjunctiva Restriction of eye movements or manifest strabismus Tilting of the head to avoid double vision
The reader is referred to Table 1 for an explanation of the recommendations grading system. www.eje-online.org b. Is it helpful to grade the severity of GO? † Grading the severity of GO is fraught with difficulties; however, classifying patients into broad categories facilitates decision making ( Fig. 1 ). † Careful assessment of the impact of GO on quality of life (QoL) by disease-specific questionnaire (GO-QoL) (42) is fundamental in deciding whether treatments used for moderate-to-severe GO (see below) are justified in patients with mild GO. c. Is it helpful to grade the activity of GO?
† Grading the activity of GO is also fraught with difficulties; however, classifying patients into active/inactive GO categories is frequently possible and greatly facilitates decision making (Fig. 1 ). The patients with a clinical activity score (CAS) R3/7 should be considered as having active GO (43, 44) .
Management of sight-threatening GO
a. How can patients with sight-threatening GO be identified? (Boxes 7 and 8) † Sight-threatening GO usually occurs in the context of dysthyroid optic neuropathy (DON). † The risk of corneal breakdown and perforation is significant when lagophthalmos is associated with poor Bell's phenomenon (45) . † Sight can also be threatened in patients with GO in the following rare circumstances: eyeball subluxation, severe forms of frozen globe in the presence of lagophthalmos, choroidal folds, and postural visual obscuration (46 Frequent monitoring of thyroid status (every 4-6 weeks) is imperative in the initial phases of treatment when changes in thyroid status are expected (IV, C).
Patients with active GO given radioiodine should be offered prophylactic steroid cover (commencing with 0.3-0.5 mg of prednisone/kg bw per day orally 1-3 days after radioiodine and tapering the dose until withdrawal w3 months later) (Ib, A). Shorter periods of glucocorticoid therapy (1-2 months) may be equally protective (IV, C).
Patients with inactive GO can safely receive radioiodine without steroid cover, as long as hypothyroidism is avoided (IIb, B), particularly if other risk factors for GO progression, such as smoking, are absent (IV, C).
Box 2 Smoking and GO
All patients with Graves' disease should be informed of the risks of smoking for GO (IV, C) emphasizing the detrimental effects of smoking on:
-Effectiveness of treatments for GO (IIb, B), -Progression of GO after radioiodine treatment (Ib, A).
If advice alone is ineffective, referral to smoking cessation clinics, or other smoking cessation strategies should be considered (IV, C).
Box 4 Simple measures that may alleviate symptoms in GO
Lubricant eye drops during the day and/or lubricant ointments at night-time are recommended for all patients with GO, who have symptoms of corneal exposure (III, B).
Patients with symptomatic diplopia should be given prisms if appropriate (IV, C).
Botulinum toxin injection may be considered for upper lid retraction in centers that have experience and expertise in this technique (IV, C).
effects than oral or retrobulbar steroids (3, 4, 47-51) ( Patients with moderate-to-severe GO usually have any one or more of the following: lid retraction R2 mm, moderate or severe soft tissue involvement, exophthalmos R3 mm above normal for race and gender, inconstant, or constant diplopia. 3. Mild GO: patients whose features of GO have only a minor impact on daily life insufficient to justify immunosuppressive or surgical treatment. They usually have only one or more of the following: minor lid retraction (!2 mm), mild soft tissue involvement, exophthalmos !3 mm above normal for race and gender, transient or no diplopia, and corneal exposure responsive to lubricants.
toxin injections can help temporize until corneal healing occurs (55) . † The effect of GCs on severe corneal exposure has never been specifically addressed. † Most of the studies on the effects of orbital decompression report a reduction in symptoms associated with exposure keratopathy; rarely severe corneal ulcers may be refractory to decompression surgery if lagophthalmos persists (56) .
Management of moderate-to-severe GO a. Does every patient with moderate-to-severe GO require treatment? (Boxes 9 and 10) † Many patients in this category should be considered for treatment, with the exception of patients who are asymptomatic or unwilling to have treatment. † Patients with moderate-to-severe and active (CAS R3/7) GO should be treated with immunosuppressive treatment modalities, while those with inactive GO may benefit from rehabilitative surgery (see below; Fig. 1 ). b. What are the non-surgical treatments of choice for moderate-to-severe GO? † Glucocorticoids. GC therapy has been used in the management of GO through oral, local (retrobulbar or subconjunctival), or i.v. routes (35) . Oral GC therapy (starting dose, 80-100 mg prednisone (or w1 mg/kg bw) or equivalent) requires high doses for prolonged periods of time.
No randomized, placebo-controlled studies have been performed. Open trials or randomized studies, in which oral GCs were compared with other treatments (47, 48, 50, (57) (58) (59) (60) (61) (62) , show a favorable response in w33-63% of patients, particularly for soft tissue changes, recent onset eye muscle involvement, and DON. The eye disease frequently flares up on tapering or withdrawing GCs. Side effects are frequent. Prolonged oral GC treatment is associated with a risk of osteoporosis (49) , which may be decreased using bisphosphonates or other antiresorptive drugs (63, 64) . Retrobulbar or subconjuctival GC therapy is less effective than oral GCs (65) . Intravenous GC pulse therapy is more effective than oral GC (response rates w80% vs w50%; GCs are safe if the cumulative dose is !8 g methylprednisolone in one course of therapy (69) . Bisphosphonates should be considered for patients receiving i.v. GCs, although no RCTs have specifically addressed this issue. † Orbital radiotherapy. The reported response rate to orbital radiotherapy (OR) in open trials is w60% (3, 4, 66) . A cumulative dose of 20 Gy per orbit fractionated in ten doses over a 2-week period is commonly used (70) , but an alternative regimen of 1 Gy per week over a 20-week period was equally effective and better tolerated (71) . Higher doses are no more effective (72) . A lower cumulative dose of 10 Gy was found to be as effective as the standard 20 Gy regimen (71) . The response to OR did not differ from oral prednisone in an RCT (60) . Two recent RCTs have shown that OR is more effective than sham irradiation in improving diplopia and eye muscle motility (73, 74) . Another RCT has questioned the efficacy of OR (75) . OR is usually well tolerated, but may cause transient exacerbation of ocular symptoms, which is preventable with concomitant GC administration (3, 66) . Data on long-term safety are reassuring (76) (77) (78) , but theoretical concerns about carcinogenesis remain for younger patients, particularly those under the age of 35 years (70, (76) (77) (78) . Although cataracts can occur earlier after OR than naturally, they are easily treated by surgery. Retinal microvascular abnormalities have been detected in a minority of patients (79) , mostly in those with concomitant severe hypertension or diabetic retinopathy, and these two comorbidities are considered absolute contraindications to OR (80, 81) . It is possible that diabetes, even in the absence of retinopathy, represents a risk factor for the development of retinal changes after OR (78) , but the evidence is less clear (77) . Thus, diabetes without retinopathy may be regarded as a relative contraindication to OR (see also Box 12) . † Combination of GC (either orally or locally) with OR is more effective than either treatment alone (57, 82) . It is unclear whether i.v. GCs with OR are more efficacious than i.v. GCs alone. † Treatments of marginal or unproven value include somatostatin analogs (83) (84) (85) (86) , azathioprine (87), ciamexone (88), and i.v. immunoglobulins (62, 89) . Two studies have shown the superiority of the combination of oral GCs and cyclosporine than either treatment alone (58, 59) . The potential usefulness of immunomodulatory agents, such as rituximab (90) or etanercept (91), has been suggested by open studies, but no RCTs have been carried out as yet.
Box 7 Glucocorticoids and orbital decompression in DON
Glucocorticoids (GCs) and surgical decompression of the orbit are the only treatments proved to be effective in patients with DON (III, B).
High-dose i.v. GCs is the preferred first-line treatment for DON (III, B ).
If the response to i.v. GCs is absent or poor after 1-2 weeks, or the dose/duration of steroid required induces significant side effects, prompt orbital decompression should be carried out (IV, C).
Orbital decompression should be offered promptly to patients with DON or corneal breakdown who cannot tolerate GCs (III, B) .
Both i.v. GC therapy and orbital decompression surgery should only be undertaken in centers with appropriate expertise (IV, C).
Box 8 Sight-threatening corneal breakdown in GO
Sight-threatening corneal breakdown should be managed as an emergency (IV, C).
The management of sight-threatening corneal breakdown includes: Frequent topical lubricants (preservative-free topical lubricants for hyperallergic patients), moisture chambers, blepharorrhaphy, tarsorrhaphy, or other temporary measures until the cornea has healed (IV, C).
Consideration of systemic GCs or surgical decompression when the above measures alone are ineffective (IV, C).
In the event of corneal perforation/severe ulceration, appropriate antibiotics, and emergency glueing, amnion membrane as shield, or corneal grafting need to be considered (IV, C).
Once the corneal breakdown is brought under control, it is imperative that treatment is offered to improve lid closure and thus prevent further episodes of corneal breakdown (IV, C).
c. Do non-surgical treatments reduce the subsequent need for rehabilitative surgery or do they adversely interfere with it? † No RCTs have been performed to investigate specifically whether non-surgical treatments reduce the subsequent need for rehabilitative surgery, so this important question remains unanswered. † The theoretical concern that radiation-induced fibrosis may reduce orbital compliance, and hence compromises subsequent therapies, is not supported by the available evidence (92, 93 Box 9 Treatment of moderate-to-severe GO that is ACTIVE
The treatment of choice for moderate-to-severe and active (CAS R3/7) GO is pulses of i.v. glucocorticoids (GCs) (Ib, A). This treatment should be undertaken in centers with appropriate expertise (IV, C).
The total cumulative dose of methylprednisolone should not exceed 8 g in one course of therapy (III, B).
Patients being treated with high-dose i.v. GC should be first screened for liver dysfunction, hypertension, history of peptic ulcer, diabetes, urine infection, and glaucoma, and then monitored for side effects (IV, C).
Bisphosphonates are recommended when long-term (O3 months) oral GC therapy (average daily dose O5 mg prednisone or equivalent) is used (Ia, A). It is reasonable to suggest the use of antiresorptive agents also when GCs are used i.v. (IV, C).
Orbital irradiation (OR) should be considered in patients with active disease who have diplopia or restricted motility (Ib, A). OR with lower cumulative doses (10 Gy) may be as effective as and better tolerated than OR with higher doses (20 Gy) (Ib, A). Doses O20 Gy are not recommended (IV, C).
Caution should be exercised before administering OR to patients younger than 35 years; OR must be avoided in patients with diabetic retinopathy or severe hypertension (III, B).
The combination of oral GCs with OR is more effective than either treatment alone (Ib, A), but randomized clinical trials indicating that the combination of i.v. GCs with OR is better than i.v. GCs alone are lacking (IV, C). (77, 78, 80, 81) , at least using a 20 Gy cumulative dose. † Diabetes and/or hypertension are not contraindications to surgical orbital decompression or other surgical treatments for GO. b. What is the best therapeutic approach to GO in childhood? † GO is rare in childhood because of the low incidence of Graves' disease in this age group (104, 105) . The eye disease is usually milder in children than in adults and often stabilizes and eventually resolves without intervention (105) . † Achieving and maintaining euthyroidism are as important objectives as in adult patients. † Exposure to smoking (active and, possibly, passive)
is probably as detrimental as in adults (106) (107) (108) . † Because of the effects on growth, GCs should be avoided unless DON is present. OR is contraindicated in children. Somatostatin analogs have Surgical management should proceed in the following sequence: orbital decompression, then squint surgery, and then lid lengthening with or followed by blepharoplasty/browplasty, since side effects of the preceding step can interfere with the step that follows (III, B) .
Rehabilitative surgery should only be performed in patients who have had inactive GO for at least 6 months (III, B).
Rehabilitative surgery should only be undertaken in centers with appropriate expertise (IV, C).
Box 11 Management of mild GO
Glucocorticoids are rarely justified in mild GO as the risks outweigh the benefits (IV, C).
Watchful waiting is appropriate for the majority of patients with mild GO (IV, C).
In a minority of patients with mild disease, quality of life may be so profoundly affected as to justify using treatments as for moderate-to-severe disease (IV, C).
been used in isolated cases, but RCTs on efficacy and safety are lacking (109) . † Orbital surgery may be necessary in the cases of severe exophthalmos, but for most patients a conservative and expectant approach is appropriate.
Summary of consensus
a. All patients with GO should (Fig. 1) : Be referred to specialist centers; Be encouraged to quit smoking; Receive prompt treatment in order to restore and maintain euthyroidism. b. Patients with sight-threatening GO should be treated with i.v. GCs as the first-line treatment; if the response is poor after 1-2 weeks, they should be submitted to urgent surgical decompression. c. The treatment of choice for moderate-to-severe GO is i.v. GCs (with or without OR) if the orbitopathy is active; surgery (orbital decompression, squint surgery, and/or eyelid surgery in this order) should be considered if the orbitopathy is inactive. d. In patients with mild GO, local measures and an expectant strategy are sufficient in most cases, but treatment may be justified if QoL is affected significantly.
In memoriam
This document is dedicated to the memory of Mark Prummel (1956 , one of the founders of EUGOGO, who greatly contributed to expanding our understanding of clinical and therapeutic aspects of GO.
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